Latest news with #ProjectManagementProfessional
Associated Press
07-03-2025
- Business
- Associated Press
Liberyx Therapeutics Announces the Appointment of Dr. Eddy Zhu as Chief CMC Officer
HONG KONG SAR, HONG KONG, March 7, 2025 / / -- Liberyx Therapeutics, a clinical-stage biopharmaceutical company developing safe, effective, and patient-friendly drugs to treat rare, pediatric neurometabolic diseases, announces the appointment of Eddy Zhu, Ph.D., as Chief CMC Officer. With extensive experience in commercial manufacturing, pharmaceutical development and regulatory approvals, Dr. Zhu is a highly accomplished scientific professional with a proven track record of success as a leader in technical R&D excellence, resulting in numerous peer-reviewed publications, multiple formulation patents, and regulatory approval. 'We are excited to have Eddy join Liberyx Therapeutics as our new Chief CMC Officer,' said Alex Yang, J.D., LL.M., Chair and Chief Executive Officer at Liberyx, 'Eddy's expertise in commercial manufacturing and pharmaceutical development will be invaluable as we continue to make significant advancements in the clinical development.' Dr. Zhu was most recently the Product Development Lead at Sanofi, where he played a critical role in pharmaceutical and non-pharmaceutical formulation and development across oral solids, liquids and injectables. Dr. Zhu also served as a director for the Parenteral Drug Development Team at WuXi AppTec, focusing on small molecule compound, peptide, peptide-drug-conjugate (PDC), and nucleotide projects. Dr. Zhu has held various senior positions with increasing responsibilities in both MNC and small startup environments. Dr. Zhu holds a Ph.D. in Applied Biological Sciences from Ghent University, a Master's degree in Food Technology from K.U. Leuven and Ghent University through the inter-university program and a Bachelor's degree in Plant Protection from Guangxi University. Dr. Zhu also holds a Project Management Professional (PMP) certification from the Project Management Institute (PMI). 'I am honored to join Liberyx team and lead the development and implementation of CMC strategies,' commented Dr. Zhu. 'I look forward to being a key contributor to accelerate Liberyx's pipeline development and bring safe and effective therapies to patients and families living with neurometabolic disorders.' About Liberyx Therapeutics Liberyx Therapeutics is an innovative clinical stage biopharmaceutical company focused on developing treatments for rare diseases affecting children, primarily neurometabolic disorders such as glycine encephalopathy (also known as nonketotic hyperglycinemia, NKH) and urea cycle disorders. Liberyx founded in 2021 with the support of Mstone Partners is currently focused on developing four pipeline candidates, including two combination approaches. Liberyx Therapeutics' largest shareholder Mstone Partners is an entrepreneurial biotech incubator in the form of a holding company which owns and manages a portfolio of drug development companies. Mstone focuses on pediatric and repurposed drugs, rare and neurodegenerative diseases, and innovative technologies for targeted indications. Since its inception in 2016, Mstone has invested in two US and two HK companies, which are now in advanced clinical-stages with the US FDA. Mstone has also established a number of portfolio companies in a centralized, hub-and-spoke model. Legal Disclaimer:
Zawya
07-02-2025
- Business
- Zawya
HE Saeed Mohammed Al Tayer meets PMI President to strengthen project management excellence and sustainability initiatives
Dubai, UAE: HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA), met with Pierre Le Manh, President and CEO of the Project Management Institute (PMI). The meeting underscored the shared commitment to advancing project management excellence and fostering collaboration in sustainable development. PMI is a not-for-profit professional membership association for project managers and program managers. PMI was started in 1969 and now has a membership of more than 2.9 million professionals worldwide. The discussions focused on leveraging PMI's extensive expertise in project management to enhance DEWA's initiatives in sustainability, innovation and operational efficiency. Both parties reaffirmed the importance of cultivating a culture of continuous improvement and learning to address the complexities of today's dynamic environment. Al Tayer emphasised DEWA's commitment to implementing pioneering projects that align with Dubai's vision for a sustainable future. He highlighted DEWA's ongoing efforts to adopt cutting-edge technologies and sustainable practices, ensuring efficiency and effectiveness in delivering transformative energy solutions. Al Tayer also highlighted the longstanding partnership between DEWA and PMI, which began in 2010 and has since achieved remarkable growth. From an initial offering of just three project management courses, the collaboration has expanded to include a comprehensive portfolio of 18 specialised courses. These cover a wide range of topics, including project management, agility and artificial intelligence (AI), underscoring DEWA's commitment to equipping its project, programme and portfolio managers with advanced knowledge and skills. As of the end of 2024, a total of 280 DEWA employees have earned the prestigious Project Management Professional (PMP) certification, with an additional 120 professionals obtaining other PMI certifications. These milestones reflect DEWA's dedication to fostering a culture of excellence in project management. Looking ahead to 2025, DEWA announced the launch of new training programmes in construction management, AI in project management and agility-focused courses. These initiatives address the evolving needs of the industry and reinforce DEWA's emphasis on innovative approaches to project execution. Pierre Le Manh commended DEWA's leadership in the global energy sector and its unwavering focus on sustainability. He expressed enthusiasm for future collaborations aimed at knowledge sharing and the adoption of best practices in project management. These efforts, he noted, will drive impactful and sustainable outcomes across projects.
Associated Press
07-02-2025
- Business
- Associated Press
Marquis Who's Who Honors Michael Stigall's Dedication to Laboratory Automation System Evaluation
UNIONDALE, NY / ACCESS Newswire / February 6, 2025 / Michael Stigall has been selected by Marquis Who's Who for his work in laboratory automation system evaluation. His extensive career has spanned various industries, including pharmaceuticals, biotechnology and finance. Mr. Stigall's expertise includes regulatory compliance, quality assurance and project management. For the past 46 years, Mr. Stigall's career has been defined by his relentless pursuit of innovation. With a diverse background spanning chemistry, computer science and project management, Mr. Stigall has carved out a unique niche for himself at the intersection of emerging technologies and regulated industries. Mr. Stigall is a principal validation engineer and consultant at USDM Life Sciences, specializing in pharmaceutical and biotechnology laboratory systems. Mr. Stigall's path in the tech world is the definition of unconventional. Originally armed with a master's degree in chemical engineering and a bachelor's degree in chemistry and German, he started his career with artificial intelligence (AI) projects long before the technology became mainstream. He would later explore different industries, including specialty chemicals, oil and gas, railroads, biotechnology and pharmaceuticals. However, his passion for new technologies in the AI space remained. 'I enjoy following new technology and finding new application areas for artificial intelligence,' Mr. Stigall explains. Pursuing his passions, he has amassed an impressive array of certifications, including Project Management Professional (PMP), Certified Information Privacy Manager (CIPM), and numerous programming and system administration accreditations. He has also earned multiple industry awards and recognitions, including his latest, the Albert Nelson Marquis Lifetime Achievement Award, which speaks to his significant contributions to laboratory automation system evaluation and his esteemed reputation. Mr. Stigall's interests go far beyond the confines of the laboratory. Drawing on his early experiences and background in teaching artificial intelligence in Europe, he has turned his attention to the modern AI space and is now exploring its real-world potential. Mr. Stigall is particularly interested in stock market investing, where he believes AI can be a powerful tool for gaining an edge. 'The coming years will be dominated by artificial intelligence,' Mr. Stigall observes. His work in the biotech space has exposed him to AI's disruptive potential and its impact on friends and family members with complex problems such as Hodgkin's Lymphoma and Alzheimer's disease, which were traditionally difficult to manage. 'AI has been a game-changer in the pharmaceutical/biotech industry, and I believe it will continue to revolutionize the field.' Mr. Stigall believes the same effect will be felt in other industries, including investments and finance. The shift has started. According to reports, some investment management firms such as BlackRock have started deploying AI-powered automated investment programs in place of human stock‐pickers. Meanwhile, regulators and stock market investors have embraced high-frequency trading (HFT) and algo-trading, also powered by artificial intelligence. Mr. Stigall sees this as the natural progression in the current stock investment space. 'AI can identify patterns and detect issues that require attention with greater accuracy than humans,' he notes. Mr. Stigall hopes to play a major role in this revolution through consulting and thought leadership. His goal is to contribute to a world where AI-powered business processes are the norm, empowering organizations to push the boundaries of what they thought possible. About Marquis Who's Who®: Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. The suite of Marquis® publications can be viewed at the official Marquis Who's Who® website, .
